Mepolizumab in childhood onset steroid dependent eosinophilic granulomatosis with polyangiitis

Abstract

more data are needed before it can be implemented as standard firstline therapy.

Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis

“…[ 5 ] To our knowledge, there are three pediatric EGPA cases successfully treated with mepolizumab in the literature. [ 6 - 8 ] In this case with relapsing and refractory myocarditis, the clinical efficacy of mepolizumab is presented without any adverse events for one year. Mepolizumab seems to be a safe treatment option in eosinophil-related end-organ inflammation for pediatric cases.…”